MAKO Surgical (Nasdaq: MAKO ) is expected to report Q3 earnings on Nov. 7. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MAKO Surgical's revenues will increase 37.3% and EPS will remain in the red.
The average estimate for revenue is $27.5 million. On the bottom line, the average EPS estimate is -$0.16.
Last quarter, MAKO Surgical logged revenue of $23.7 million. GAAP reported sales were 27% higher than the prior-year quarter's $18.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.20. GAAP EPS were -$0.20 for Q2 versus -$0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 73.1%, 260 basis points better than the prior-year quarter. Operating margin was -35.9%, 1,810 basis points better than the prior-year quarter. Net margin was -36.1%, 1,720 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $107.0 million. The average EPS estimate is -$0.74.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,165 members out of 1,209 rating the stock outperform, and 44 members rating it underperform. Among 250 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 239 give MAKO Surgical a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is hold, with an average price target of $34.57.